Graticule positions itself as a “Research Network Operator and Evidence Generator,” serving life sciences companies, health systems, and hospitals. Its core value is helping customers conduct real-world studies, support clinical trials, monitor safety, and generate payer evidence through a global real-world data network, EHR data, and research execution capabilities. It is more like a combination of “data network + research services + specialized software modules” than a standardized self-service SaaS product for the mass market.
Its product lineup includes Study Source, Episcope, CLEHR, and Patient Finder. Study Source focuses on global real-world data access, feasibility assessment, and evidence planning. Episcope provides end-to-end real-world evidence study planning and execution, supported by epidemiologists and data scientists. CLEHR emphasizes a digital EHR-to-Sponsor eSource network. Patient Finder is used for precise patient screening, clinical decision support, and trial recruitment. The materials particularly highlight hard-to-access data scenarios such as rare diseases, long-term follow-up, clinical notes, imaging reports, and non-U.S. data.
The website does not disclose plans, pricing, free trials, or payment methods. Its commercial model is likely based on consulting, project-based work, or enterprise contracts. On the integration side, Graticule mentions partnerships with global health systems, hospitals, data aggregators, HIT platforms, and AI/data partners, and supports EHR-to-Sponsor integration. However, it does not list specific systems such as Epic or Cerner, nor does it publish API documentation.
Healthcare data businesses inherently depend on strong compliance capabilities. The materials mention GDPR, IRB/Ethics approvals, federated and remote analytics models, and operational compliance leadership, but do not clearly state certifications such as HIPAA, SOC 2, or ISO 27001. For collaboration, Episcope emphasizes that its expert team can act as an extension of the customer’s organization and coordinate cross-functional stakeholders, but there is no explanation of in-product permission management.
Its strengths are vertical focus and a relatively deep combination of data network access and research execution capabilities. It is suitable for pharmaceutical companies, medical device companies, and hospitals that need global RWD, rare disease research, long-term follow-up, patient recruitment, and EHR-based evidence generation. The drawbacks are limited disclosure around commercial and technical details: pricing, deployment, APIs, and security certifications are all opaque, so buyers should conduct thorough due diligence before procurement.
Access from China is unknown. Because the service involves cross-border healthcare data and collaboration with European and U.S. health systems, Chinese customers should evaluate not only network accessibility but also data export requirements, privacy compliance, contract payment, and local alternatives. Comparable options include TriNetX, IQVIA, Komodo Health, as well as Chinese real-world research service providers such as Yidu Tech and LinkDoc.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on graticule.life official site.
graticule.life is an United States SaaS Tools provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of Limited (proxy recommended). Click "Visit Official Site" to reach graticule.life directly.